Vector-borne diseases (VBDs) are a significant public health concern in India, posing a substantial burden on the healthcare system. These diseases, transmitted by vectors like mosquitoes, ticks, and fleas, include Malaria, Dengue, Chikungunya, and Japanese Encephalitis, among others.
India, with its tropical climate and high population density, provides an ideal environment for vector proliferation. Malaria, primarily caused by Plasmodium falciparum and Plasmodium vivax, is highly prevalent, with approximately 1.1 million cases reported in 2019. Dengue, another critical VBD, witnessed an alarming surge, with over 157,000 cases in the same year. The prevalence of other VBDs like Chikungunya and Japanese Encephalitis also remains high, contributing to the overall disease burden.
The management of VBDs in India is fraught with challenges. These include inadequate surveillance, limitations in diagnostic facilities, and resistance to vector control measures. Additionally, socio-economic factors such as poor sanitation, lack of awareness, and limited access to healthcare services exacerbate the situation.
Effective management of VBDs requires a multifaceted approach. Early diagnosis and prompt treatment are critical to reducing morbidity and mortality. Strengthening surveillance systems can facilitate early detection and timely intervention. Vector control strategies, including the use of insecticide-treated nets and indoor residual spraying, should be intensified. Importantly, community participation and education are crucial to ensuring the success of these strategies.
Vector-borne diseases pose a significant threat to public health in India. Despite the challenges, comprehensive strategies encompassing surveillance, diagnosis, treatment, vector control, and community participation can substantially mitigate this burden. As healthcare professionals, understanding the prevalence and management of these diseases is vital to improving patient outcomes and public health.
1.
Research uncovers hidden Australian skin cancer epidemic
2.
What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?
3.
The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.
4.
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise.
5.
Using MRD Status to Deescalate Multiple Myeloma Therapy
1.
Understanding Purpura Fulminans: Causes, Symptoms and Treatment Options
2.
The Importance of Maintaining Normal Calcium Levels in Your Body
3.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
4.
Metabolic Symbiosis Within the Tumor Niche: Mechanisms, Clinical Implications, and Therapeutic Opportunities
5.
A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
2.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
3.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
4.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
5.
Latest Advances in Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation